Objective: The study aimed to investigate cyclin-dependent kinase 14 (CDK14) and its co-function with Wnt signaling pathway on cell proliferation, migration and invasion in ovarian cancer. Methods: CDK14 expressions were detected by quantitative real-time polymerase chain reaction. The expressions c-Myc, cyclinD1, PFTK1, ki67 and OGT were examined by Western blot. MTT assay was applied to observe cell proliferation after transfection of pEGFP-N1/CDK14-siRNA and pEGFP-N1 into SKOV3 cells, and scratch test and Transwell assay to observe invasion and migration ability. Transfected tumor model in nude mice was established. Results: CDK14 was upregulated in the ovarian cancer tissues and cell lines (both p < 0.05). Expressions of downstream molecules in Wnt signaling pathway as well as the proliferation, invasion and migration ability of the SKOV3 cells were reduced when CDK14 was inhibited (all p < 0.05). The expression of β-catenin in the nucleus was also decreased when CDK14 was inhibited (p < 0.05). In the transfected tumor model of nude mice, the results showed, compared with the pEGFP-N1 group and blank control group, that the expressions of c-Myc, cyclinD1, PFTK1, ki67 and OGT in the pEGFP-N1/CDK14-siRNA group in the transplantation tumor tissues decreased significantly (all p < 0.05). Conclusion: CDK14 suppression-mediated Wnt signaling pathway can inhibit cell proliferation, invasion and migration in ovarian cancer.

Keywords:
Cell proliferation, Cell migration, Cell invasion, Ovarian cancer, Cyclin-dependent kinase 14, Wnt signaling pathway, SKOV3, β-Catenin
1.
Aghajanian C, Goff B, Nycum LR, et al: Final overall survival and safety analysis of oceans, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2015;139:10-16.
2.
Colombo N, Peiretti M, Parma G, et al: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v23-v30.
3.
Ledermann JA, Raja FA, Fotopoulou C, et al: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6):vi24-vi32.
4.
McCluggage WG: Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011;43:420-432.
5.
Liu Z, Liu J, Segura MF, et al: MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 2012;228:204-215.
6.
Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
7.
Cicenas J, Valius M: The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409-1418.
8.
Parry D, Guzi T, Shanahan F, et al: Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9:2344-2353.
9.
Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-166.
10.
Yang T, Chen JY: Identification and cellular localization of human PFTAIRE1. Gene 2001;267:165-172.
11.
Duan C, Liu Y, Lu L, et al: CDK14 contributes to reactive gliosis via interaction with cyclin Y in rat model of spinal cord injury. J Mol Neurosci 2015;57:571-579.
12.
Tsuji K, Yasui K, Gen Y, et al: PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet 2010;198:118-125.
13.
Yang L, Zhu J, Huang H, et al: PFTK1 promotes gastric cancer progression by regulating proliferation, migration and invasion. PLoS One 2015;10:e0140451.
14.
Miyagaki H, Yamasaki M, Miyata H, et al: Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. Br J Cancer 2012;106:947-954.
15.
Sun T, Co NN, Wong N: PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochem Biophys Res Commun 2014;449:163-168.
16.
Gu X, Wang Y, Wang H, et al: Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer. Med Oncol 2015;32:195.
17.
Zheng L, Zhou Z, He Z: Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer. Int J Clin Exp Pathol 2015;8:14005-14012.
18.
Zhang W, Liu R, Tang C, et al: PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer. Int J Biol Macromol 2016;85:405-416.
19.
Jiang M, Gao Y, Yang T, et al: Cyclin Y, a novel membrane-associated cyclin, interacts with PFTK1. FEBS Lett 2009;583:2171-2178.
20.
Liu D, Finley RL Jr: Cyclin Y is a novel conserved cyclin essential for development in drosophila. Genetics 2010;184:1025-1035.
21.
Davidson G, Shen J, Huang YL, et al: Cell cycle control of Wnt receptor activation. Dev Cell 2009;17:788-799.
22.
Zeng X, Huang H, Tamai K, et al: Initiation of Wnt signaling: control of Wnt coreceptor lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008;135:367-375.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.